Previous 10 | Next 10 |
2024-04-29 09:06:36 ET Bristol-Myers Squibb Company (BMY) Q1 2024 Earnings Conference Call April 25, 2024, 8:00 AM ET Company Participants Tim Power - Vice President, Investor Relations Chris Boerner - Board Chair and Chief Executive Officer David Elkins - Execut...
2024-04-29 08:51:30 ET Summary Immatics N.V., a European T-Cell receptor therapy company, is expected to release clinical data on all four of its candidates in 2024. The company's main focus is on developing T-cell receptor therapies for the treatment of solid tumors. Immatics...
2024-04-29 06:56:23 ET Bristol Myers Squibb ( NYSE: BMY ) and Repertoire Immune Medicines have entered a multi-year strategic collaboration to develop tolerizing vaccines for up to three autoimmune diseases.... Read the full article on Seeking Alpha For further detai...
Repertoire® Immune Medicines and Bristol Myers Squibb Announce Multi-Year Strategic Collaboration to Develop Tolerizing Vaccines for Autoimmune Diseases PR Newswire Collaboration combines Repertoire's industry leading DECODE™ platform that uniquely maps the immune ...
2024-04-27 15:39:17 ET More on Amgen, Cullinan Oncology, etc. Amgen: I Prefer To Chase Value And Dividends Amgen: The Giant With An Impressive Pipeline Move Over Eli Lilly: Amgen Could Be The Next Obesity Wonder Stock Cullinan Therapeutics expands into autoim...
2024-04-27 09:29:58 ET Summary A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates. Companies with upcoming pay dates. Introduction The D...
2024-04-27 08:15:00 ET Summary AT&T and Bristol-Myers Squibb are two beaten-down stocks with attractive dividend yields. AT&T has solid operating fundamentals and a low valuation, while Bristol-Myers Squibb has a strong pipeline and is undervalued. Both stocks offer po...
2024-04-27 06:39:22 ET Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha , iTunes , Spotify . Read the full article on Seeking Alpha For further details see: Wall Street Breakfast: What Moved Ma...
2024-04-26 14:32:03 ET More on Bristol, Sanofi, Takeda Bristol-Myers Squibb Stock: Gloomy Q1 Earnings Trigger Justified Sell-Off Bristol-Myers Squibb Company (BMY) Q1 2024 Earnings Call Transcript Sanofi 2024 Q1 - Results - Earnings Call Presentation Takeda s...
Recommendation based on results from CheckMate -901, the first Phase 3 trial with an immunotherapy-chemotherapy combination to demonstrate a survival benefit versus standard-of-care chemotherapy alone in cisplatin-eligible adults with unresectable or metastatic urothelial carcinoma If...
News, Short Squeeze, Breakout and More Instantly...
Bristol-Myers Squibb Company Company Name:
BMY Stock Symbol:
NYSE Market:
Bristol-Myers Squibb Company Website:
NORTHAMPTON, MA / ACCESSWIRE / July 22, 2024 / Bristol Myers Squibb Company Our Approach to ESG At BMS, we understand that the future of our company, employees, communities, and the planet are inextricably linked. Our passion for making an impact extends beyond the discovery, development a...
The Application is based on Phase 3 CheckMate - 9DW trial results demonstrating improved survival with Opdivo plus Yervoy compared to investigator’s choice of lenvatinib or sorafenib in this patient population Bristol Myers Squibb (NYSE: ...
SBTi validation affirms BMS' long-standing commitment to environmental stewardship PRINCETON, NJ / ACCESSWIRE / July 18, 2024 / Bristol Myers Squibb (NYSE:BMY) today announced validation for its near-term and net-zero science-based targets from the Science Based Targets initiative (SBTi), ...